GlassScriptPhysician profile
George A Evans
NPI 1124073788
$16,060.93
in general payments reported to CMS, 2019-2025
62 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,512 · 2020: $2,822 · 2021: $2,726 · 2022: $1,993 · 2023: $1,667 · 2024: $2,402 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,008.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,374.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,432.71 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,314.50 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Abbvie INC. | $1,115.42 | 2019-2025 | |
| Amarin Pharma, INC. | $1,079.71 | 2019-2022 | |
| Glaxosmithkline, LLC. | $926.66 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $685.77 | 2019-2025 | |
| Lilly USA, LLC | $626.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $455.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Esperion Therapeutics, INC. | $443.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $427.02 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $416.96 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $375.72 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $295.06 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $284.99 | 2023-2025 | Sunosi, Auvelity |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.